The available evidence on improving the metabolic control of Medtronic-Minimed CGMS in real time in adults is scarce but of good quality and demonstrated a decrease in blood glucose levels, although the information about reducing the frequency of hypo- and hyperglycemias is scarce and of low quality. For the paediatric population, the limited evidence available, both in improving metabolic control and in reducing the frequency of hypo- and hyperglycemias with the retrospective Medtronic-Minimed CGMS does not allow to make conclusions about its effectiveness. Finally, there is no evidence for pregnant women. And for the security, although the studies included in the review measure it with secondary outcomes, data suggest that the system is safe and that adverse effects are mild. Considering the available evidence, the CGMS in real time should be restricted to the following potential candidates: DM1 Adults patients with a lack of glycemic control (HbA1c >=8,1%) treated with an intensive insuline therapy (Continuous subcutaneous insulin infusion or multiple insulin injections), including a 3 months review.